In the dynamic landscape of biopharmaceutical innovation, Ajinomoto Bio-Pharma Services (ABS) has firmly established itself as a vanguard of progress. A subsidiary of the Tokyo-based Ajinomoto Co., Inc., this global, fully integrated contract development and manufacturing organization (CDMO) is consistently pushing the envelope of pharmaceutical advancement. But to truly appreciate the depths of their pioneering […]